Literature DB >> 1552330

A retrospective study of radiolabeled granulocyte kinetics in patients with systemic vasculitis.

N D Jonker1, A M Peters, G Gaskin, C D Pusey, J P Lavender.   

Abstract

Patients with systemic vasculitis, including Wegener's granulomatosis (WG) and microscopic polyarteritis (MP), may undergo white cell scanning for the investigation of infective complications and/or occult fever. In a retrospective study of 12 patients with systemic vasculitis (six each of WG and MP), all with renal disease, we observed increase diffuse lung radioactivity soon after the injection of 111In-labeled granulocytes or 99mTc-HMPAO-labeled leukocytes in all patients with WG and in three with MP. Lung activity was quantified by comparison with the liver or spleen. The lung:liver count rate ratio per pixel, 1-1.5 hr after injection, in patients with systemic vasculitis was 0.87 (s.d. 0.25), significantly higher (p less than 0.001) than the ratio 0.38 (0.13) in patient controls who had normal white cell scans. The majority of patients with systemic vasculitis had scintigraphic evidence of abnormal splenic function. Two had focal splenic defects, while 7 had increased labeled cell uptake. Nine of the patients with vasculitis showed cell migration into the gut, presumably as a result of vasculitis, and in 6 it was prominent. Focal nasal uptake was found in 5/7 patients with systemic vasculitis who had their heads imaged, and may be specific for WG. Although all patients had renal disease, there was scintigraphic evidence of diffuse parenchymal renal uptake of 111In-labeled granulocytes in only one (with MP). The presence of anti-neutrophil cytoplasmic antibodies did not correlate with any abnormality or with lung uptake. Systemic vasculitis is associated with abnormalities of granulocyte kinetics, particularly involving the lung and spleen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552330

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Nasal mucosal thickening simulating a tumor: potential for misdiagnosis in brain perfusion imaging.

Authors:  L G Flores; S Jinnouchi; S Nagamachi; T Ohnishi; S Futami; Y Okuda; N Tsuru; K Watanabe
Journal:  Ann Nucl Med       Date:  1996-08       Impact factor: 2.668

2.  In situ evidence of pulmonary endothelial activation in patients with granulomatosis with polyangiitis and systemic sclerosis.

Authors:  Leticia Kawano-Dourado; Alexandre M Ab'Saber; Vera Luiza Capelozzi; Carla Valeri; Carmen Sílvia Valente Barbas
Journal:  Lung       Date:  2015-03-19       Impact factor: 2.584

3.  Quantification of pulmonary uptake of indium-111 labelled granulocytes in inflammatory bowel disease.

Authors:  W Y Ussov; A M Peters; H J Hodgson; J M Hughes
Journal:  Eur J Nucl Med       Date:  1994-01

4.  Labelling of leucocytes with technetium-99m exametazime causes in vitro upregulation of granulocyte CD11b without correlation to tissue uptake in vivo.

Authors:  S Almer; O Ljunghusen; J Lundahl
Journal:  Eur J Nucl Med       Date:  1996-06

Review 5.  The contribution of nuclear medicine to the patient with infection.

Authors:  W Becker
Journal:  Eur J Nucl Med       Date:  1995-10

6.  Clinical value of gallium-67 scintigraphy in assessment of disease activity in Wegener's granulomatosis.

Authors:  R H J A Slart; P L Jager; L Poot; D A Piers; J-W Cohen Tervaert; C A Stegeman
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

7.  Splenic infarction is not rare in granulomatosis with polyangiitis.

Authors:  Onay Gercik; Sebnem Karasu; Dilek Solmaz; Zeki Soypacaci; Fulya Cakalagaoglu; Servet Akar
Journal:  Clin Rheumatol       Date:  2020-02-27       Impact factor: 2.980

8.  In vivo imaging of hepatic neutrophil migration in severe alcoholic hepatitis with 111In-radiolabelled leucocytes.

Authors:  Jonathan R Potts; Neda Farahi; Mark R Howard; Mark R Taylor; Sarah Heard; Arun N Shankar; Graeme J Alexander; Edwin R Chilvers; Sumita Verma; A Michael Peters
Journal:  Biosci Rep       Date:  2018-07-31       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.